CB-839 + irinotecan hydrochloride + panitumumab

CB-839 + irinotecan hydrochloride + panitumumab is an investigational combination therapy comprising three agents with distinct mechanisms of action for the treatment of cancer, particularly metastatic colorectal cancer. - **CB-839 (telaglenastat)** is a small molecule inhibitor of glutaminase (GLS), an enzyme critical for converting glutamine to glutamate in tumor cell metabolism. By inhibiting GLS, CB-839 disrupts energy production and biosynthesis in tumor cells, leading to reduced proliferation and increased apoptosis[1][2][3][4][5][7]. - **Irinotecan hydrochloride** is a topoisomerase I inhibitor that interferes with DNA replication in rapidly dividing cells by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA damage and cell death. - **Panitumumab** is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It binds EGFR on tumor cells, blocking ligand-induced activation and downstream signaling pathways involved in cell proliferation and survival. Panitumumab induces internalization of EGFR and inhibits tumor growth[6][8][10]. This combination aims to target metabolic vulnerabilities (glutaminase inhibition), disrupt DNA replication (topoisomerase inhibition), and block growth factor signaling (EGFR antagonism) for synergistic antineoplastic effects.

Brand names

Vectibix

Other names

telaglenastatirinotecanpanitumumab